Extrapulmonary benefits and pharmacogenomics in lung transplant recipients with Cystic Fibrosis on Elexacaftor/Tezacaftor/Ivacaftor (ETI) therapy

Journal of Cystic Fibrosis · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles